Italy patient-facing document QC checklist

1. Inventory and applicability

Confirm that the package contains every document needed for the study's actual pathways. This normally includes the main information and consent form and the separate privacy information and consent. Add recruitment material, sample consent, optional sub-study consent, pregnancy follow-up material, legal-representative forms, age-appropriate minor material and witness wording when applicable.

Map each document to a CTIS category and to the population or activity it covers. Record “not applicable” only when the study genuinely lacks that activity. Use the Italy Part II document checklist to test completeness.

2. Correct national source and version

Confirm that the main form was developed against the CCNCE consent guidance and models dated 27 May 2026. Confirm that the privacy document follows the separate CCNCE model announced on 13 August 2026. Check whether AIFA has updated either source since the review date shown above.

Use the current EU recruitment and informed-consent procedure template. Version 2.0 becomes the replacement form on 1 September 2026. For a submission spanning that date, use version 2.0 and retain evidence of the source version used.

3. Document control

Put the document title, language, version and date in the header or footer. Make those details identical on every page and in the CTIS file name. Confirm that the protocol number, EU trial number, sponsor name, lay title, principal investigator and site name match controlled source data.

Remove tracked changes, comments, hidden text, drafting instructions and unresolved placeholders. Check section numbering, page numbering, contents lists and cross-references after PDF conversion. Verify that blank signature fields remain blank in the submission copy.

Use one national core form. Limit site variables to genuine local facts. The June 2026 CCNCE FAQ says that authorised consent documents are nationally valid and cannot be altered locally. Route later changes through sponsor document control and the ethics modification process where required.

4. Italian language and readability

The Italian version must read as original participant communication, not as a literal regulatory translation. Check terminology with a qualified Italian medical translator and a second reviewer. Resolve ambiguous source text with the medical writer before finalising the translation.

Use short sentences, active voice and everyday terms. Expand acronyms on first use and remove avoidable English terminology. Explain unavoidable technical concepts where they first appear. Test headings, bullet lists, type size, contrast and white space. Check the final rendered document on screen and in print.

Adapt the language to age, health literacy and decision-making capacity. Arrange accessible formats and language mediation where needed. For minor documents, verify that the parent form, adolescent assent and child information sheet do not contradict one another.

5. Voluntariness and balance

State that participation is voluntary and that refusal or withdrawal will not affect ordinary care, benefits or legal rights. Remove any waiver of liability or language suggesting that the participant must remain in the trial.

Balance risks and benefits. Do not describe investigational treatment as proven, safe or better. State when direct benefit is uncertain or not expected. Phase I and healthy-volunteer material must make unknown risk and non-therapeutic purpose especially clear.

Describe reimbursements as actual trial-related expenses or another specifically approved arrangement. Match every amount and condition to the Part II financial document. Remove promotional emphasis and any suggestion that accepting risk earns a reward.

6. Protocol and procedure consistency

Cross-check study purpose, arms, randomisation ratio, placebo, blinding, duration, visit count, treatment periods and follow-up against the protocol. Recalculate blood volume, sampling frequency and optional procedures. Distinguish standard care from research-only procedures.

Check expected and foreseeable risks against the investigator's brochure or summary of product characteristics and the current risk assessment. Ensure reproductive precautions, washout periods, prohibited medicines and lifestyle restrictions are identical across the protocol, consent and participant tools.

Verify withdrawal, early termination, lost-to-follow-up and safety follow-up language. Do not promise immediate deletion of data or samples when law, safety or scientific-integrity duties limit what can be withdrawn.

7. Decision-critical content

The opening pages should tell the reader why they are invited, what the study tests, what participation changes, the main risks and burdens, expected or absent benefit, alternatives and the right to decline. Do not hide these facts in a long appendix.

Check costs, reimbursement, injury insurance, complaint routes and urgent contacts. Confirm that every phone number is complete and that the operating hours match the service offered. Check how results and important incidental findings will be communicated.

Use the patient information and consent guide for the required content and signature process.

8. Privacy separation and consistency

Keep the detailed GDPR information and data-processing consent in a distinct Italian privacy document. Identify the controller or controllers, contact points, purposes, legal bases, recipients, processors, transfers, safeguards, retention and rights according to the actual data flow.

Cross-check the privacy document against the protocol, data-management plan, vendor list, laboratories, central imaging, electronic systems and contracts. Explain coding accurately. Do not call coded or pseudonymised data anonymous. Verify that international-transfer language reflects the destination and safeguard actually used.

Align withdrawal language across the clinical consent, privacy notice and sample consent. Explain that withdrawal can stop new optional collection while data already lawfully collected may need to remain in the trial database and regulatory archive.

9. Samples, genetics and future use

List every sample type, amount, collection point, analysis, storage location, transfer and retention period. Separate samples required for the main protocol from optional future storage. Give optional genetic analysis, biobanking and secondary research distinct choices where applicable.

Check that the sample information identifies governance, access, coding, commercial or academic collaborators, possible international transfers, return of individual findings and destruction or anonymisation at the end of storage. Use the secondary-use consent guide.

10. Population-specific safeguards

For minors, confirm the legally operative parent or guardian consent, age-appropriate information and the child's assent or objection. Provide a new adult consent process for participants who turn 18 during the trial. Use the minor consent and assent guide.

For an adult with limited capacity, verify the legal representative's authority and scope. Provide adapted information to the participant and respect an objection. Use the limited-capacity consent guide.

For emergency enrolment, confirm all Article 35 conditions and a prompt deferred-consent pathway. Use the emergency-enrolment guide.

For a capable person unable to write, confirm impartial-witness wording and an acceptable alternative means of recording consent. Use the impartial-witness guide.

For pregnancy follow-up, distinguish a trial participant from a pregnant partner who is a separate data subject. Use the pregnancy follow-up guide.

11. Signatures and consent workflow

Check the participant and investigator signature, name, date, place and time fields against the applicable CCNCE model. Add legal-representative, parent and witness fields only for the pathway concerned. Make optional choices independently answerable.

The form must support the real workflow. It should allow the person providing information to record that questions were answered, understanding was checked and a copy was given. Electronic workflows need identity, audit trail, version control, access to information and delivery of the completed record.

12. Final bilingual and rendered-file review

If an English master is retained, perform a clause-level reconciliation after Italian review so that neither language has missing or extra obligations. Treat the approved Italian document as the participant-facing controlled version.

Open every final file. Inspect page breaks, clipped text, symbols, accented characters, fillable fields, hyperlinks and signature blocks. Search the folder for obsolete versions and quarantine them from the upload set. Then compare the CTIS upload inventory with the approved document register.

Return to the Italy CTIS guide hub for the full guide series.